Parkinson’s Disease: Dopamine Receptor Agonists and Monoamine Oxidase B Inhibitors @ProfessorDaveExplains
Parkinson’s Disease: Dopamine Receptor Agonists and Monoamine Oxidase B Inhibitors  @ProfessorDaveExplains
Uploaded October 2026 | Updated November 2026, 3 hours ago
Parkinson's disease is the second most common neurodegenerative disease behind Alzheimer's disease. What is its pathophysiology? What are the pharmacological strategies towards treatment? Let's find out!

Script by Michael Keith

Watch the whole Pharmacology playlist: bit.ly/ProfDavePharma

General Chemistry Tutorials: bit.ly/ProfDaveGenChem
Organic Chemistry Tutorials: bit.ly/ProfDaveOrgChem
Biochemistry Tutorials: bit.ly/ProfDaveBiochem
Biology/Genetics Tutorials: bit.ly/ProfDaveBio
Anatomy & Physiology Tutorials: bit.ly/ProfDaveAnatPhys
Biopsychology Tutorials: bit.ly/ProfDaveBiopsych
Microbiology/Infectious Diseases Tutorials: bit.ly/ProfDaveMicrobio

History of Drugs Videos: bit.ly/ProfDaveHistoryDrugs
Immunology Tutorials: bit.ly/ProfDaveImmuno

EMAIL► ProfessorDaveExplains@gmail.com
PATREON► patreon.com/ProfessorDaveExplains

Check out "Is This Wi-Fi Organic?", my book on disarming pseudoscience!
Amazon: amzn.to/2HtNpVH
Bookshop: bit.ly/39cKADM
Barnes and Noble: bit.ly/3pUjmrn
Parkinson’s Disease: Dopamine Receptor Agonists and Monoamine Oxidase B InhibitorsAblative of AccompanimentRussell Brand Sucks a LotEPA Head Lee Zeldin is a Freaking NightmareReacting to the Bill Nye/Ken Ham Debate (Evolution vs. Creationism)Moon Landing Deniers Are Idiots: Bart Sibrel Debunked (Part 2 of 2)Sabine Hossenfelder: More Exposed Than Ever! (Racism Edition)Jay Bhattacharya and Martin Kulldorff: Colleagues in FraudulenceMammalian Diversity Part 3: PlacentalsGrifter Tier List 2026 Expansion Pack!Medieval Poland Part 1: Mieszko and His LineIntroduction to the Weak Interaction
Professor Dave Explains |

Parkinson’s Disease: Dopamine Receptor Agonists and Monoamine Oxidase B Inhibitors

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER